140 related articles for article (PubMed ID: 29115437)
41. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
42. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
43. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.
Ghosh JC; Altieri DC
Clin Cancer Res; 2005 Jun; 11(12):4580-8. PubMed ID: 15958644
[TBL] [Abstract][Full Text] [Related]
44. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
[TBL] [Abstract][Full Text] [Related]
45. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
46. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
47. The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Spiegelberg D; Mortensen AC; Lundsten S; Brown CJ; Lane DP; Nestor M
Cancer Res; 2018 Sep; 78(17):5084-5093. PubMed ID: 30026328
[TBL] [Abstract][Full Text] [Related]
48. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
49. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
Molecules; 2019 May; 24(10):. PubMed ID: 31121972
[TBL] [Abstract][Full Text] [Related]
51. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
52. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.
Li M; Zhang Z; Hill DL; Chen X; Wang H; Zhang R
Cancer Res; 2005 Sep; 65(18):8200-8. PubMed ID: 16166295
[TBL] [Abstract][Full Text] [Related]
53. The novel anthraquinone derivative IMP1338 induces death of human cancer cells by p53-independent S and G2/M cell cycle arrest.
Choi HK; Ryu H; Son AR; Seo B; Hwang SG; Song JY; Ahn J
Biomed Pharmacother; 2016 Apr; 79():308-14. PubMed ID: 27044842
[TBL] [Abstract][Full Text] [Related]
54. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
55. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells.
Chen X; Wong P; Radany E; Wong JY
Cancer Biother Radiopharm; 2009 Dec; 24(6):689-99. PubMed ID: 20025549
[TBL] [Abstract][Full Text] [Related]
56. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
57. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function.
Liu XF; Xia YF; Li MZ; Wang HM; He YX; Zheng ML; Yang HL; Huang WL
Cell Biol Int; 2006 Mar; 30(3):283-7. PubMed ID: 16448826
[TBL] [Abstract][Full Text] [Related]
58. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
59. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
60. Methylselenol, a selenium metabolite, modulates p53 pathway and inhibits the growth of colon cancer xenografts in Balb/c mice.
Zeng H; Cheng WH; Johnson LK
J Nutr Biochem; 2013 May; 24(5):776-80. PubMed ID: 22841391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
